Biocartis Announces the End of its Alliance with bioMérieux
News Nov 29, 2013
Biocartis has announced that bioMérieux and Biocartis have signed an agreement to end their alliance for the development and commercialization of the integrated molecular biology system, Idylla™ (previously Apollo), in the field of microbiology molecular diagnostics. bioMérieux will return all rights on the Idylla™ platform to Biocartis.
In November 2010, Biocartis had entered into a strategic alliance with bioMérieux to develop and commercialize microbiology assays on Biocartis’ fully integrated molecular diagnostics platform Idylla™.
With the ending of the alliance, Biocartis has regained all the rights relating to the use of its platform in the microbiology field, and is free to explore new strategic options in that respect.
Rudi Pauwels, CEO of Biocartis, commented: “We will definitely keep microbiology assays in the menu of tests on the Idylla™ platform, either through internal developments or via a new partner.”
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
Diagnosis and Treatment of Heart and Circulatory Diseases a Top Priority for the UKNews
NHS commits to a new focus around heart and circulatory diseases in 10 year planREAD MORE
Synthetic Material That Detects Enzymatic ActivityNews
Scientists integrate protein and polymer building blocks to create stimulus-responsive systemsREAD MORE
3rd International Conference on Diagnostic Microbiology and Infectious Diseases
Sep 24 - Sep 25, 2018